A Systematic Review of MicroRNAs Involved in Cervical Cancer Progression

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Apr 3

PMID 33803022

Citations 14

Authors

Rhafaela Lima Causin

Ana Julia Aguiar de Freitas

Cassio Murilo Trovo Hidalgo Filho

Ricardo Dos Reis

Rui Manuel Reis

Marcia Maria Chiquitelli Marques

Affiliations

Soon will be listed here.

Abstract

To obtain a better understanding on the role of microRNAs in the progression of cervical cancer, a systematic review was performed to analyze cervical cancer microRNA studies. We provide an overview of the studies investigating microRNA expression in relation to cervical cancer (CC) progression, highlighting their common outcomes and target gene interactions according to the regulatory pathways. To achieve this, we systematically searched through PubMed MEDLINE, EMBASE, and Google Scholar for all articles between April 2010 and April 2020, in accordance with the PICO acronym (participants, interventions, comparisons, outcomes). From 27 published reports, totaling 1721 cases and 1361 noncancerous control tissue samples, 26 differentially expressed microRNAs (DEmiRNAs) were identified in different International Federation of Gynecology and Obstetrics (FIGO) stages of cervical cancer development. It was identified that some of the dysregulated microRNAs were associated with specific stages of cervical cancer development. The results indicated that DEmiRNAs in different stages of cervical cancer were functionally involved in several key hallmarks of cancer, such as evading growth suppressors, enabling replicative immortality, activation of invasion and metastasis, resisting cell death, and sustained proliferative signaling. These dysregulated microRNAs could play an important role in cervical cancer's development. Some of the stage-specific microRNAs can also be used as biomarkers for cancer classification and monitoring the progression of cervical cancer.

Citing Articles

Diagnostics and Therapy for Malignant Tumors.

Tsai C, Wang C, Chang H, Chang P, Chang C, Chu T Biomedicines. 2025; 12(12.

PMID: 39767566 PMC: 11726849. DOI: 10.3390/biomedicines12122659.

The Natural History of Cervical Cancer and the Case for MicroRNAs: Is Human Papillomavirus Infection the Whole Story?.

Palomino-Vizcaino G, Banuelos-Villegas E, Alvarez-Salas L Int J Mol Sci. 2024; 25(23.

PMID: 39684702 PMC: 11641362. DOI: 10.3390/ijms252312991.

Understanding the role of miRNAs in cervical cancer pathogenesis and therapeutic responses.

Chauhan P, Pramodh S, Hussain A, Elsori D, Lakhanpal S, Kumar R Front Cell Dev Biol. 2024; 12:1397945.

PMID: 39263322 PMC: 11387185. DOI: 10.3389/fcell.2024.1397945.

Editorial: Searching for causes of infertility: from pathophysiologic mechanisms to therapeutic strategies.

Kamieniczna M, Olszewska M, Malcher A, Stokowy T, Gunes S Front Genet. 2024; 15:1432026.

PMID: 38988834 PMC: 11233803. DOI: 10.3389/fgene.2024.1432026.

miRNAs that regulate apoptosis in breast cancer and cervical cancer.

Beilankouhi E, Maghsoodi M, Zamani Sani M, Khosroshahi N, Zarezadeh R, Nargesi M Cell Biochem Biophys. 2024; 82(3):1993-2006.

PMID: 38969951 DOI: 10.1007/s12013-024-01405-7.

References

Wang N, Zhou Y, Zheng L, Li H . MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. Gynecol Oncol. 2014; 134(1):129-37. DOI: 10.1016/j.ygyno.2014.04.047. View

Gonzalez-Quintana V, Palma-Berre L, Campos-Parra A, Lopez-Urrutia E, Peralta-Zaragoza O, Vazquez-Romo R . MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review). Oncol Rep. 2015; 35(1):3-12. DOI: 10.3892/or.2015.4369. View

Shan D, Shang Y, Hu T . MicroRNA-411 Inhibits Cervical Cancer Progression by Directly Targeting STAT3. Oncol Res. 2018; 27(3):349-358. PMC: 7848402. DOI: 10.3727/096504018X15247361080118. View

Zhao Y, Wang J, Chen X, Wu Y, Wu Q . Values of three different preoperative regimens in comprehensive treatment for young patients with stage Ib2 cervical cancer. Asian Pac J Cancer Prev. 2012; 13(4):1487-9. DOI: 10.7314/apjcp.2012.13.4.1487. View

Ou R, Zhu L, Zhao L, Li W, Tao F, Lu Y . HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway. J Cell Physiol. 2018; 234(3):2659-2671. DOI: 10.1002/jcp.27080. View

da Rosa M, Medeiros L, Dornelles Rosa D, Bozzeti M, Silva F, Silva B . [Human papillomavirus and cervical neoplasia]. Cad Saude Publica. 2009; 25(5):953-64. DOI: 10.1590/s0102-311x2009000500002. View

Liao H, Pan Y, Pan Y, Shen J, Qi Q, Zhong L . MicroRNA‑874 is downregulated in cervical cancer and inhibits cancer progression by directly targeting ETS1. Oncol Rep. 2018; 40(4):2389-2398. DOI: 10.3892/or.2018.6624. View

Pal A, Kundu R . Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020; 10:3116. PMC: 6985034. DOI: 10.3389/fmicb.2019.03116. View

Green J, Kirwan J, Tierney J, Symonds P, Fresco L, Collingwood M . Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001; 358(9284):781-6. DOI: 10.1016/S0140-6736(01)05965-7. View

10.

Zheng T, Wang J, Chen X, Liu L . Role of microRNA in anticancer drug resistance. Int J Cancer. 2009; 126(1):2-10. DOI: 10.1002/ijc.24782. View

11.

Shao S, Wang C, Wang S, Zhang H, Zhang Y . LncRNA STXBP5-AS1 suppressed cervical cancer progression via targeting miR-96-5p/PTEN axis. Biomed Pharmacother. 2019; 117:109082. DOI: 10.1016/j.biopha.2019.109082. View

12.

Hanna J, Hossain G, Kocerha J . The Potential for microRNA Therapeutics and Clinical Research. Front Genet. 2019; 10:478. PMC: 6532434. DOI: 10.3389/fgene.2019.00478. View

13.

Zhang Y, Xu Z . miR-93 enhances cell proliferation by directly targeting CDKN1A in nasopharyngeal carcinoma. Oncol Lett. 2018; 15(2):1723-1727. PMC: 5774441. DOI: 10.3892/ol.2017.7492. View

14.

He Y, Lin J, Ding Y, Liu G, Luo Y, Huang M . A systematic study on dysregulated microRNAs in cervical cancer development. Int J Cancer. 2015; 138(6):1312-27. DOI: 10.1002/ijc.29618. View

15.

Huang Y, Li Y, Wang F, Lv W, Xie X, Cheng X . Over-Expressed miR-224 Promotes the Progression of Cervical Cancer via Targeting RASSF8. PLoS One. 2016; 11(9):e0162378. PMC: 5023165. DOI: 10.1371/journal.pone.0162378. View

16.

Wang Y, Wang L, Wang W, Guo X . Overexpression of circular RNA hsa_circ_0001038 promotes cervical cancer cell progression by acting as a ceRNA for miR-337-3p to regulate cyclin-M3 and metastasis-associated in colon cancer 1 expression. Gene. 2019; 733:144273. DOI: 10.1016/j.gene.2019.144273. View

17.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

18.

Ferracin M, Negrini M . Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2015; 15(10):1369-81. DOI: 10.1586/14737159.2015.1081058. View

19.

Sepulveda C, Prado R . Effective cervical cytology screening programmes in middle-income countries: the Chilean experience. Cancer Detect Prev. 2005; 29(5):405-11. DOI: 10.1016/j.cdp.2005.07.001. View

20.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View